Last quarter (Q2 2022), OptiBiotix Health's total revenue was £―, a decrease of ― from the same quarter last year. In Q2, OptiBiotix Health's net income was £―. See OptiBiotix Health’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Nov 18
Total Revenue	-	£ 457.00K	£ 2.21M	£ 1.52M	£ 744.88K	£ 514.29K
Cost of Revenue	-	£ 213.00K	£ 1.09M	£ 643.43K	£ 352.08K	£ 162.78K
Gross Profit	-	£ 244.00K	£ 1.12M	£ 879.82K	£ 392.80K	£ 351.51K
Operating Expense	-	£ 2.52M	£ 2.49M	£ 1.99M	£ 2.56M	£ 1.85M
Operating Income	-	£ -2.28M	£ -1.37M	£ -1.11M	£ -2.17M	£ -1.50M
Net Non Operating Interest Income Expense	-	£ -210.00K	£ 47.48K	£ 44.86K	£ -44.36K	£ 169.00
Other Income Expense	-	£ -4.93M	-	-	-	-
Pretax Income	-	£ 2.44M	£ 6.18M	£ 5.71M	£ -2.49M	£ -1.95M
Tax Provision	-	£ -146.00K	£ -84.52K	£ -91.64K	£ -123.47K	£ -54.37K
Earnings From Equity Interest Net Of Tax	-	£ -83.00K	-	-	-	-
Net Income Common Stockholders	-	£ 2.59M	£ 6.26M	£ 5.80M	£ -2.37M	£ -1.92M
Basic EPS	-	£ 0.03	£ 0.07	£ 0.07	£ -0.03	£ -0.02
Diluted EPS	-	£ 0.03	£ 0.07	£ 0.06	£ -0.03	£ -0.02
Basic Average Shares	-	£ 87.57M	£ 87.57M	£ 87.21M	£ 85.26M	£ 82.23M
Diluted Average Shares	-	£ 95.54M	£ 95.54M	£ 95.57M	£ 85.26M	£ 82.23M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	-	£ 2.74M	£ -3.58M	£ -2.63M	£ 2.91M	£ 2.01M
Net Income From Continuing And Discontinued Operation	-	£ 2.59M	£ 6.26M	£ 5.80M	£ -2.37M	£ -1.92M
Normalized Income	-	£ -19.35M	£ 6.09M	£ 1.45M	£ -2.62M	£ -1.92M
Interest Expense	-	-	-	-	£ 44.47K	£ 0.00
EBIT	-	£ 2.65M	£ 6.22M	£ 5.76M	£ -2.45M	£ -1.95M
EBITDA	-	£ 2.88M	£ 6.22M	£ 5.76M	£ -2.23M	£ -1.81M

Currency in GBP

OptiBiotix Health Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing